Interaction of human dipeptidyl peptidase IV and human immunodeficiency virus type-1 transcription transactivator in Sf9 cells

Virology Journal

Volumn 7, Issue , 2010, Pages

  Tansi, Felista L ^a   Blanchard, Véronique ^a   Berger, Markus ^a   Tauber, Rudolf ^a   Reutter, Werner ^a   Fan, Hua ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACULOVIRUS VECTOR; DIPEPTIDYL PEPTIDASE IV; TRANSACTIVATOR PROTEIN; DPP4 PROTEIN, HUMAN;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LEPIDOPTERA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; ANIMAL; ARMYWORM; BACULOVIRUS; CELL LINE; CONFOCAL MICROSCOPY; GENE VECTOR; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOPRECIPITATION; METABOLISM; PATHOGENICITY; PHOSPHORYLATION; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS 1; SPODOPTERA FRUGIPERDA;

ANIMALS; BACULOVIRIDAE; CELL LINE; DIPEPTIDYL PEPTIDASE 4; GENETIC VECTORS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; PHOSPHORYLATION; PROTEIN BINDING; SPODOPTERA; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77957734776     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-267     Document Type: Article

References (56)

1. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. M Hegen G Niedobitek CE Klein H Stein B Fleischer, J Immunol 1990 144 2908 2914 1969875
2. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Y Misumi Y Hayashi F Arakawa Y Ikehara, Biochim Biophys Acta 1992 1131 333 336 1352704
3. Dipeptidyl aminopeptidase I: application in sequencing of peptides. PX Callahan JK McDonald S Ellis, Fed Proc 1972 31 1105 1113 4338109
4. Dipeptidyl peptidase IV, a kidney microvillus serine proteinase: evidence for its large subunit molecular weight and endopeptidase activity. AJ Kenny AG Booth EJ Wood AR Young, Biochem Soc Trans 1976 4 347 348 1001687
5. Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. C Hanski T Huhle W Reutter, Biol Chem Hoppe Seyler 1985 366 1169 1176 2868739
6. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. K Löster K Zeilinger D Schuppan W Reutter, Biochem Biophys Res Commun 1995 217 341 348 10.1006/bbrc.1995.2782 8526932
7. Direct association of adenosine deaminase with a T cell activation antigen, CD26. J Kameoka T Tanaka Y Nojima SF Schlossman C Morimoto, Science 1993 261 466 469 10.1126/science.8101391 8101391
8. Binding of adenosine deaminase to the lymphocyte surface via CD26. I De Meester G Vanham L Kestens G Vanhoof E Bosmans P Gigase S Scharpe, Eur J Immunol 1994 24 566 570 10.1002/eji.1830240311 7907293
9. The structure and function of CD26 in the T-cell immune response. C Morimoto SF Schlossman, Immunol Rev 1998 161 55 70 10.1111/j.1600-065X.1998. tb01571.x 9553764
10. CD26 antigen and HIV fusion? CC Broder O Nussbaum WG Gutheil WW Bachovchin EA Berger, Science 1994 264 1156 1159 author reply 1162-1155 10.1126/science.7909959 7909959
11. T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. C Callebaut B Krust E Jacotot AG Hovanessian, Science 1993 262 2045 2050 10.1126/science.7903479 7903479
12. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. S Struyf P Proost S Sozzani A Mantovani A Wuyts E De Clercq D Schols J Van Damme, J Immunol 1998 161 2672 2675 9743322
13. Macrophage-derived chemokine (MDC). A Mantovani PA Gray J Van Damme S Sozzani, J Leukoc Biol 2000 68 400 404 10985257
14. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. T Oravecz M Pall G Roderiquez MD Gorrell M Ditto NY Nguyen R Boykins E Unsworth MA Norcross, J Exp Med 1997 186 1865 1872 10.1084/jem.186.11.1865 9382885
15. RANTES: a versatile and controversial chemokine. V Appay SL Rowland-Jones, Trends Immunol 2001 22 83 87 10.1016/S1471-4906(00)01812-3 11286708
16. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. T Shioda H Kato Y Ohnishi K Tashiro M Ikegawa EE Nakayama H Hu A Kato Y Sakai H Liu T Honjo A Nomoto A Iwamoto C Morimoto Y Nagai, Proc Natl Acad Sci USA 1998 95 6331 6336 10.1073/pnas.95.11.6331 9600965
17. Comodulation of CXCR4 and CD26 in human lymphocytes. C Herrera C Morimoto J Blanco J Mallol F Arenzana C Lluis R Franco, J Biol Chem 2001 276 19532 19539 10.1074/jbc.M004586200 11278278
18. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. WG Gutheil M Subramanyam GR Flentke DG Sanford E Munoz BT Huber WW Bachovchin, Proc Natl Acad Sci USA 1994 91 6594 6598 10.1073/pnas.91.14.6594 7912830
19. The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding. RE Smith JW Talhouk EE Brown SE Edgar, AIDS Res Hum Retroviruses 1998 14 851 868 10.1089/aid.1998.14. 851 9671214
20. Good or evil: CD26 and HIV infection. T Ohtsuki H Tsuda C Morimoto, J Dermatol Sci 2000 22 152 160 10.1016/S0923-1811(99)00081-X 10698152
21. Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26). WA Weihofen J Liu W Reutter W Saenger H Fan, J Biol Chem 2005 280 14911 14917 10.1074/jbc.M413400200 15695814
22. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. H Xiao C Neuveut HL Tiffany M Benkirane EA Rich PM Murphy KT Jeang, Proc Natl Acad Sci USA 2000 97 11466 11471 10.1073/pnas.97.21. 11466 11027346
23. Regulation of HIV expression: mechanisms of action of Tat and Rev. KT Jeang Y Chang B Berkhout ML Hammarskjold D Rekosh, AIDS 1991 5 Suppl 2 3 14 10.1097/00002030-199101001-00002 1845057
24. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. C Dingwall I Ernberg MJ Gait SM Green S Heaphy J Karn AD Lowe M Singh MA Skinner, EMBO J 1990 9 4145 4153 2249668
25. Tackling Tat. J Karn, J Mol Biol 1999 293 235 254 10.1006/jmbi.1999.3060 10550206
26. Tat as a transcriptional activator and a potential therapeutic target for HIV-1. A Gatignol KT Jeang, Adv Pharmacol 2000 48 209 227 full-text 10987092
27. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. MC Huigen W Kamp HS Nottet, Eur J Clin Invest 2004 34 57 66 10.1111/j.1365-2362.2004.01282.x 14984439
28. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. A Vendeville F Rayne A Bonhoure N Bettache P Montcourrier B Beaumelle, Mol Biol Cell 2004 15 2347 2360 10.1091/mbc.E03-12-0921 15020715
29. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. M Tyagi M Rusnati M Presta M Giacca, J Biol Chem 2001 276 3254 3261 10.1074/jbc.M006701200 11024024
30. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. G Barillari C Sgadari V Fiorelli F Samaniego S Colombini V Manzari A Modesti BC Nair A Cafaro M Sturzl B Ensoli, Blood 1999 94 663 672 10397733
31. New perspectives in cell adhesion: RGD and integrins. E Ruoslahti MD Pierschbacher, Science 1987 238 491 497 10.1126/science.2821619 2821619
32. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. MO Westendorp M Li-Weber RW Frank PH Krammer, J Virol 1994 68 4177 4185 8207793
33. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. L Buonaguro FM Buonaguro G Giraldo B Ensoli, J Virol 1994 68 2677 2682 8139045
34. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. L Huang I Bosch W Hofmann J Sodroski AB Pardee, J Virol 1998 72 8952 8960 9765440
35. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. TK Howcroft K Strebel MA Martin DS Singer, Science 1993 260 1320 1322 10.1126/science.8493575 8493575
36. On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation. K Verhoef M Bauer A Meyerhans B Berkhout, AIDS Res Hum Retroviruses 1998 14 1553 1559 10.1089/aid.1998.14.1553 9840288
37. HIV-1 tat transcriptional activity is regulated by acetylation. RE Kiernan C Vanhulle L Schiltz E Adam H Xiao F Maudoux C Calomme A Burny Y Nakatani KT Jeang M Benkirane C Van Lint, EMBO J 1999 18 6106 6118 10.1093/emboj/18.21.6106 10545121
38. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. T Ammosova R Berro M Jerebtsova A Jackson S Charles Z Klase W Southerland VR Gordeuk F Kashanchi S Nekhai, Retrovirology 2006 3 78 10.1186/1742-4690-3-78 17083724
39. Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. R Van Duyne R Easley W Wu R Berro C Pedati Z Klase K Kehn-Hall EK Flynn DE Symer F Kashanchi, Retrovirology 2008 5 40 10.1186/1742-4690-5-40 18498648
40. Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26. J Blanco I Marie C Callebaut E Jacotot B Krust AG Hovanessian, Exp cell Res 1996 225 102 111 10.1006/excr.1996.0161 8635502
41. The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. S Wrenger T Hoffmann J Faust C Mrestani-Klaus W Brandt K Neubert M Kraft S Olek R Frank S Ansorge D Reinhold, J Biol Chem 1997 272 30283 30288 10.1074/jbc.272.48.30283 9374514
42. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. MC Boulanger C Liang RS Russell R Lin MT Bedford MA Wainberg S Richard, J Virol 2005 79 124 131 10.1128/JVI.79.1.124-131.2005 15596808 (Pubitemid 39648370)
43. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. V Bres RE Kiernan LK Linares C Chable-Bessia O Plechakova C Treand S Emiliani JM Peloponese KT Jeang O Coux M Scheffner M Benkirane, Nat Cell Biol 2003 5 754 761 10.1038/ncb1023 12883554
44. The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. S Wrenger D Reinhold T Hoffmann M Kraft R Frank J Faust K Neubert S Ansorge, FEBS Lett 1996 383 145 149 10.1016/0014-5793(96)00221-9 8925885
45. Extracellular HIV-1 Tat protein activates phosphatidylinositol 3- and Akt/PKB kinases in CD4+ T lymphoblastoid Jurkat cells. PZG Borgatti ML Colamussi D Gibellini M Previati LL Cantley S Capitani, Eur J Immunol 1997 11 2805 2811 10.1002/eji.1830271110 (Pubitemid 27478347)
46. Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. DBA Gibellini S Pierpaoli L Bertolaso D Milani S Capitani M La Placa G Zauli, J Immunol 1998 160 3891 3898 9558095
47. Tat protein from HIV-1 activates MAP kinase in granular neurons and glial cells from rat cerebellum. ALC Menegon F Benfenati F Valtorta, Biochem Biophys Res Commun 1997 238 800 805 10.1006/bbrc.1997.7393 9325171
48. Early phosphorylation events induced by DPIV/CD26-specific inhibitors. T Kahne K Neubert J Faust S Ansorge, Cell Immunol 1998 189 60 66 10.1006/cimm.1998.1355 9758695
49. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. DA Fox RE Hussey KA Fitzgerald O Acuto C Poole L Palley JF Daley SF Schlossman EL Reinherz, J Immunol 1984 133 1250 1256 6205075
50. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. CJ Li DJ Friedman C Wang V Metelev AB Pardee, Science 1995 268 429 431 10.1126/science.7716549 7716549
51. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. B Richter E Bandeira-Echtler K Bergerhoff C Lerch, Vasc Health Risk Manag 2008 4 753 768 19065993
52. Insulin-dependent phosphorylation of DPP IV in liver. Evidence for a role of compartmentalized c-Src. N Bilodeau A Fiset GG Poirier S Fortier MC Gingras JN Lavoie RL Faure, FEBS J 2006 273 992 1003 10.1111/j.1742-4658.2006.05125.x 16478473
53. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. K Aertgeerts S Ye MG Tennant ML Kraus J Rogers BC Sang RJ Skene DR Webb GS Prasad, Protein Sci 2004 13 412 421 10.1110/ps.03460604 14718659
54. Crystal structure of HIV-1 Tat complexed with human P-TEFb. TH Tahirov ND Babayeva K Varzavand JJ Cooper SC Sedore DH Price, Nature 2010 465 747 751 10.1038/nature09131 20535204
55. Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells. J Dobers M Zimmermann-Kordmann M Leddermann T Schewe W Reutter H Fan, Protein Expr Purif 2002 25 527 532 10.1016/S1046-5928(02)00043-8 12182835
56. DNA sequencing with chain-terminating inhibitors. F Sanger S Nicklen AR Coulson, Proc Natl Acad Sci USA 1977 74 5463 5467 10.1073/pnas.74.12.5463 271968